Published in Arthritis Res on January 11, 2001
Increased transendothelial migration of scleroderma lymphocytes. Ann Rheum Dis (2004) 0.83
Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis (2004) 0.80
Atherosclerosis--an inflammatory disease. N Engl J Med (1999) 59.28
The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature (1993) 27.07
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med (1999) 6.84
Differentiation of monocytes into dendritic cells in a model of transendothelial trafficking. Science (1998) 4.97
Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum (1990) 4.39
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum (1998) 4.37
Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol (1991) 2.69
Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum (1996) 1.83
The adhesion molecules used by monocytes for migration across endothelium include CD11a/CD18, CD11b/CD18, and VLA-4 on monocytes and ICAM-1, VCAM-1, and other ligands on endothelium. J Immunol (1995) 1.66
Quantitation and kinetics of blood monocyte migration to acute inflammatory reactions, and IL-1 alpha, tumor necrosis factor-alpha, and IFN-gamma. J Immunol (1993) 1.38
VLA-4 integrin can mediate CD11/CD18-independent transendothelial migration of human monocytes. J Clin Invest (1993) 1.37
New insights into the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2000) 1.26
Monocytes use either CD11/CD18 or VLA-4 to migrate across human endothelium in vitro. J Immunol (1994) 1.17
Identification of subsets of human T cells capable of enhanced transendothelial migration. J Immunol (1992) 1.12
Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T cell activation. J Immunol (1998) 1.08
Expression of E-selectin, ICAM-1 and VCAM-1 on bronchial biopsies from allergic and non-allergic asthmatic patients. Int Arch Allergy Immunol (1995) 1.05
Functional differentiation of dendritic cells in rheumatoid arthritis: role of CD86 in the synovium. J Immunol (1996) 1.03
IL-1 activation of endothelium supports VLA-4 (CD49d/CD29)-mediated monocyte transendothelial migration to C5a, MIP-1 alpha, RANTES, and PAF but inhibits migration to MCP-1: a regulatory role for endothelium-derived MCP-1. J Leukoc Biol (1995) 0.99
Monocyte production during inflammation. Comp Immunol Microbiol Infect Dis (1985) 0.98
Induction of monocyte chemoattractant protein-1 synthesis in human monocytes during transendothelial migration in vitro. Circ Res (1995) 0.95
Interactions between interleukin-2-activated lymphocytes and vascular endothelium: binding to and migration across specialized and non-specialized endothelia. Immunology (1992) 0.95
Induction of persistent T cell hyporesponsiveness in vivo by monoclonal antibody to ICAM-1 in patients with rheumatoid arthritis. J Immunol (1995) 0.95
Transcriptional regulation of the human intercellular adhesion molecule-1 gene: a short overview. Immunobiology (1995) 0.94
Cross-linking of CD14 molecules on monocytes results in a CD11/CD18- and ICAM-1-dependent adherence to cytokine-stimulated human endothelial cells. J Immunol (1993) 0.93
Contribution of CD11a/CD18, CD11b/CD18, ICAM-1 (CD54) and -2 (CD102) to human monocyte migration through endothelium and connective tissue fibroblast barriers. Eur J Immunol (1998) 0.93
Regulation of chemokine-induced transendothelial migration of T lymphocytes by endothelial activation: differential effects on naive and memory T cells. J Leukoc Biol (2000) 0.93
The role of T-lymphocytes and cytokines in rheumatoid arthritis. Scand J Rheumatol (1996) 0.91
The effect of alendronate on cytokine production, adhesion molecule expression, and transendothelial migration of human peripheral blood mononuclear cells. Calcif Tissue Int (1998) 0.88
Adhesion molecule expression and response to chemotactic agents of human monocyte-derived macrophages. Clin Exp Immunol (1996) 0.87
Activated T cells acquire endothelial cell surface determinants during transendothelial migration. J Immunol (1999) 0.86
Pathways of mononuclear cell infiltration in rheumatoid synovitis. Rheumatol Int (1989) 0.86
Inhibition of the transendothelial migration of human lymphocytes but not monocytes by phosphodiesterase inhibitors. Clin Exp Immunol (1996) 0.85
Expression of adhesion molecules on synovial fluid and peripheral blood monocytes in patients with inflammatory joint disease and osteoarthritis. Ann Rheum Dis (1999) 0.83
In vitro models of lymphocyte transendothelial migration. Invasion Metastasis (1992) 0.82
Targeting of cells involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (1999) 0.82
The migration of lymphocytes and polymorphonuclear leukocytes across the endothelial wall of the absorbing peripheral lymphatic vessel. J Submicrosc Cytol Pathol (1990) 0.79
The adhesion and transendothelial migration of human T lymphocyte subsets. Behring Inst Mitt (1993) 0.79
Changes in the expression of adhesion molecules as peripheral blood monocytes differentiate into peritoneal macrophages. Nephrol Dial Transplant (1996) 0.78
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum (1998) 8.69
Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 7.04
The complete nucleotide sequence of an infectious clone of cauliflower mosaic virus by M13mp7 shotgun sequencing. Nucleic Acids Res (1981) 5.70
Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis. Rheumatology (Oxford) (2004) 4.56
Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren's Syndrome. Ann Rheum Dis (1996) 3.68
Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide. Ann Rheum Dis (2002) 3.53
Range of antinuclear antibodies in "healthy" individuals. Arthritis Rheum (1997) 3.29
Alendronate for the treatment of osteoporosis in men. N Engl J Med (2000) 3.11
Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset. Arthritis Res (2000) 3.03
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis (2011) 2.74
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. J Immunol (1999) 2.74
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Ann Rheum Dis (2008) 2.55
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) (2006) 2.36
Rapid diagnosis of Entamoeba infection by using Entamoeba and Entamoeba histolytica stool antigen detection kits. J Clin Microbiol (1995) 2.31
World Health Organization and International League of Associations for Rheumatology core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J Rheumatol Suppl (1994) 2.23
Haemostatic abnormalities persist despite glycaemic improvement by insulin therapy in lean type 2 diabetic patients. Thromb Haemost (1994) 2.09
Entamoeba histolytica and Entamoeba dispar infection in children in Bangladesh. J Infect Dis (1997) 1.95
Assessing remission in clinical practice. Rheumatology (Oxford) (2007) 1.92
A critical evaluation of enzyme immunoassays for detection of antinuclear autoantibodies of defined specificities. I. Precision, sensitivity, and specificity. Arthritis Rheum (1999) 1.85
Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis (2001) 1.78
Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison. Ann Rheum Dis (2006) 1.77
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis (2005) 1.77
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann Rheum Dis (2005) 1.77
Practical progress in realisation of early diagnosis and treatment of patients with suspected rheumatoid arthritis: results from two matched questionnaires within three years. Ann Rheum Dis (2002) 1.75
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis (2007) 1.70
The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. Rheumatology (Oxford) (2002) 1.69
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2011. Ann Rheum Dis (2012) 1.67
Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.67
Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum (2008) 1.66
Highly increased levels of tumor necrosis factor-alpha and other proinflammatory cytokines in psoriatic arthritis synovial fluid. J Rheumatol (1997) 1.65
Methotrexate as the "anchor drug" for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol (2004) 1.65
Tumor shedding and coagulation. Science (1981) 1.64
Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A pilot study. Arthritis Rheum (1992) 1.61
25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids (2001) 1.61
Fine specificity of anti-Ro(SSA) autoantibodies and clinical manifestations in patients with systemic lupus erythematosus. J Rheumatol (1996) 1.61
Concurrence of sarcoidosis and aortitis: case report and review of the literature. Ann Rheum Dis (2000) 1.57
Effect of litter size on plasma cholesterol and insulin and some liver and adipose tissue enzymes in adult rodents. J Nutr (1984) 1.50
Demonstration of a new antinuclear antibody (anti-RA33) that is highly specific for rheumatoid arthritis. Arthritis Rheum (1989) 1.48
Heterogeneity of immunoregulatory T-cell subsets in systemic lupus erythematosus. Correlation with clinical features. Am J Med (1982) 1.46
Systemic lupus erythematosus patients exhibit functional deficiencies of endothelial progenitor cells. Rheumatology (Oxford) (2008) 1.46
Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. Arthritis Rheum (2009) 1.46
Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) (1999) 1.45
Clinical utility and serological connections of anti-RA33 antibodies in systemic lupus erythematosus. J Rheumatol (1994) 1.44
Broadband ultrasound attenuation: a new diagnostic method in osteoporosis. AJR Am J Roentgenol (1990) 1.44
Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol (1996) 1.42
Antinuclear antibodies in patients with chronic idiopathic autoimmune thrombocytopenia followed 2-30 years. Am J Hematol (1989) 1.42
Rheumatoid arthritis and B lymphocyte alloantigen HLA-DRw4. J Rheumatol (1980) 1.41
Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis (2010) 1.38
A patient with evidence of two underlying diseases causing hypercalcaemia. Nephrol Dial Transplant (2001) 1.38
Responder cells in the human autologous mixed lymphocyte reaction. J Clin Invest (1981) 1.37
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis (2010) 1.34
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other rheumatic diseases (May 2002). Ann Rheum Dis (2002) 1.33
Interaction of fibronectin with C1q and its collagen-like fragment (CLF). FEBS Lett (1981) 1.33
Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture. J Clin Invest (1982) 1.33
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis (2008) 1.31
HLA antigens in inflammatory bowel disease. Gastroenterology (1982) 1.31
Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. Ann Rheum Dis (2007) 1.30
Acetoacetate formation by liver slices from adult and infant rats. Biochem J (1964) 1.28
The human autologous mixed lymphocyte reaction. III. Immune circuits. J Immunol (1982) 1.27
In vitro correction of the interleukin 2 defect of autoimmune mice. Eur J Immunol (1983) 1.27
Purification and partial sequencing of the nuclear autoantigen RA33 shows that it is indistinguishable from the A2 protein of the heterogeneous nuclear ribonucleoprotein complex. J Clin Invest (1992) 1.26
Acetoacetate formation by livers of young and adult rats. Biol Neonat (1967) 1.26
The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. Arthritis Rheum (1992) 1.25
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006. Ann Rheum Dis (2006) 1.25
Use of "spydergrams" to present and interpret SF-36 health-related quality of life data across rheumatic diseases. Ann Rheum Dis (2009) 1.25
Updated consensus statement on biological agents for the treatment of rheumatoid arthritis and other immune mediated inflammatory diseases (May 2003). Ann Rheum Dis (2003) 1.25
Updated consensus statement on biological agents, specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2004. Ann Rheum Dis (2004) 1.24
Tumour necrosis factor and other proinflammatory cytokines in systemic lupus erythematosus: a rationale for therapeutic intervention. Lupus (2004) 1.23
Serum levels of osteoprotegerin increase with age in a healthy adult population. Bone (2003) 1.23
Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum (2007) 1.23
The human autologous mixed lymphocyte reaction. I. Suppression by macrophages and T cells. J Immunol (1981) 1.21
Clinical evaluation of chemomechanical caries removal in primary molars and its acceptance by patients. Caries Res (2001) 1.20
Characterization of a vitamin D receptor knockout mouse as a model of colorectal hyperproliferation and DNA damage. Carcinogenesis (2001) 1.20
Autoantibody to the nuclear antigen RA33: a marker for early rheumatoid arthritis. Br J Rheumatol (1993) 1.20
Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis (2007) 1.18
A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol (2000) 1.17
Immunocytochemical localization of the extracellular calcium-sensing receptor in normal and malignant human large intestinal mucosa. J Histochem Cytochem (2000) 1.17
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis (2011) 1.17
Congenital unilateral muscle hyperplasia of the hand with ulnar deviation of the fingers. J Hand Surg Br (1994) 1.15
25-hydroxy-vitamin d metabolism in human colon cancer cells during tumor progression. Biochem Biophys Res Commun (2001) 1.15
Interleukin-1 is essential for systemic inflammatory bone loss. Ann Rheum Dis (2010) 1.15
Patients with rheumatoid arthritis in clinical care. Ann Rheum Dis (2004) 1.14
Enhanced serum levels of thiobarbituric-acid-reactive substances in diabetes mellitus. Am J Med (1995) 1.14
Mechanism and regulation of intestinal phosphate absorption. Miner Electrolyte Metab (1990) 1.13
Serum osteocalcin concentrations in patients with rheumatoid arthritis. Ann Rheum Dis (1989) 1.12
Incomplete lupus erythematosus: results of a multicentre study under the supervision of the EULAR Standing Committee on International Clinical Studies Including Therapeutic Trials (ESCISIT). Rheumatology (Oxford) (2001) 1.10
[Post-traumatic carpal collapse (SLAC- and SNAC-wrist)--stage classification and therapeutic possibilities]. Handchir Mikrochir Plast Chir (1997) 1.10
Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum (1995) 1.09
Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. Rheumatology (Oxford) (2004) 1.09
Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab (1999) 1.08